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Abstract
Chagas disease (CD) is the principal cause of congestive heart failure (CHF) in areas 
where the disease is endemic and migration has increased the likelihood of these dis‐
eases being the probable cause of CHF in other countries of the world. Sudden cardiac 
death (SCD) is the most common cause of death in CD (55–65%). Implantable cardio‐
verter defibrillator (ICD) is useful in the secondary prevention of SCD, but there is less 
information regarding primary prevention. The evidence supporting the use of cardiac 
resynchronization therapy (CRT) in CHF of chagasic etiology is poor; however, one 
should apply current guidelines regarding the insertion of these devices in patients with 
Chagas disease and CHF.
Keywords: Chagas disease, congestive heart failure, sudden cardiac death, implantable 
cardioverter defibrillator, cardiac resynchronization therapy
1. Introduction
Chagas disease (CD), also known as American trypanosomiasis, was discovered by Carlos 
Chagas in 1909, is caused by infection with the protozoa Trypanosoma cruzi (T. cruzi). CD had 
become widely recognized by the World Health Organization as a neglected tropical disease 
[1]. T. cruzi may be transmitted through blood transfusion, organ transplantation, congeni‐
tal transmission, or ingestion of contaminated food [2, 3]. However, T. cruzi infection most 
often occurs via vectorial transmission by a type of reduviid bug called a triatomine. T. cruzi 
is excreted in the feces of an infected triatomine bug onto human skin or near mucous mem‐
branes. The parasites breach the dermis through excoriations in the skin and gain systemic 
access [4]. Inoculation is followed by an incubation period of 1 to 2 weeks; it is characterized by 
parasitemia and subsequent immune response; and 10–30% of infected individuals will begin to 
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exhibit nonspecific symptoms of acute CD, including abdominal pain, anorexia, fever, lymph‐
adenopathy, rash, malaise and localized swelling around the site of infection [5]. However, the 
majority of individuals become asymptomatic carriers of T. cruzi or indeterminate phase.
Approximately one‐third of patients progress to the determinate phase in which cardiac 
symptoms and signs arise from progressive myofibril fibrosis and conduction system injury 
[6]. This phase begins after several decades during which there are no clinically overt symp‐
toms of organ damage or abnormal electrocardiographic results; 30–40% of asymptomatic 
carriers will develop chronic CD characterized by dilated cardiomyopathy leading to conges‐
tive heart failure (CHF) and/or by development of gastrointestinal disorders [7].
The Pan American Health Organization (PAHO) estimates between 8 and 12 million people 
seropositive [8]. Annual deaths are of less variable, ranging from 10,600 to 12,500 [9]. In Latin 
American countries, 100 million people are at risk of infection and 300,000 new cases are 
reported each year [10].
The United States (US) Centers for Disease Control and Prevention have reported more than 
300,000 immigrants living in the US infected with T. cruzi [11]. In 2010 CD was responsible 
for 550,000 (274,000–1,069,000) disability‐adjusted life years (DALYs), a measure that captures 
both premature mortality and nonfatal health loss [12].
The diagnosis of chronic CD should be suspected in patients from endemic areas (Central and 
South America) with dilated cardiomyopathy or electrocardiographic abnormalities like right 
bundle‐branch block associated or not with left anterior hemiblock (LAHB). Definitive diagno‐
sis is based on serology to detect immunoglobulin G antibodies to T. cruzi, using at least two 
serological tests of different principles. The most commonly used are enzyme‐linked immuno‐
sorbent assay (ELISA), indirect immunofluorescence (IIF) and indirect hemagglutination (IHA).
2. Sudden cardiac death and Chagas disease
Sudden cardiac death (SCD) is the most common cause of death in CD (55–65%), followed by 
congestive heart failure (CHF) (25–30%) and cerebral or pulmonary embolism (10–15%) [13]. 
Although SCD may affect asymptomatic patients, it affects patients with evidence of chronic 
heart disease, particularly those with CHF in the majority of cases [14]. The prevalence of SCD 
in CD patients with CHF is about 46% [15], whereas in a general unselected CD population 
is 29% [16]. The prevalence also changes in different areas, varying from 29% in non‐endemic 
to 37% in endemic areas [16, 17]. Most SCD cases are in patients with manifest chagasic car‐
diomyopathy and mainly between 30 and 50 years of age, being rare after the sixth decade of 
life [14]. On the other hand, up to 20% of patients who die suddenly do not report previous 
symptoms [14]. SCD may exceptionally occur as a result of rupturing of the left ventricular 
apical aneurysm, massive cardioembolic stroke, or pulmonary embolism [18, 19]. However, in 
the overwhelming majority of cases, it is essentially an arrhythmic phenomenon.
In a study of ten chagasic patients who died suddenly with an ambulatory Holter, bradyar‐
rhythmias were the final event in one patient. Ventricular fibrillation (VF) was the final arrhyth‐
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mia in nine patients; torsades de pointes was the precursor in six and sustained ventricular 
tachycardia (VT) in three patients [20]. From the studies carried out in Chagas’ disease 
patients receiving implantable cardioverter defibrillator (ICD) therapy, it has become clear 
that sustained VT is the most frequently observed life‐threatening ventricular arrhythmia, 
although in about 30% of patients who develop VF without having sustained TV as a pre‐
cursor [21].
The mechanism underlying the tachyarrhythmia episodes in Chagas’ disease patients is 
micro‐reentry. There is impressive reparative confluent fibrosis intermingled with normal 
myocardium. In addition, there is also a diffuse mononuclear cell infiltrate. The association 
of these two myocardial abnormalities can provoke the appearance of multiple areas of slow 
conduction in the vicinity of scars, forming foci of reentry disseminated throughout the heart, 
mainly in the epicardial areas [22, 23]. Another point that deserves further consideration is 
the autonomic dysfunction; studies in patients with chronic CD have clearly demonstrated 
parasympathetic derangement in patients with chronic CD [24]. In a study of 52 patients with 
Chagas cardiomyopathy with pacemaker or ICD, we found more positive serological response 
against 2e‐m2MAChR (antibody that recognizes the muscarinic acetyl choline receptor type 
II) than in patients with pacemaker or ICD without CD (32.7 vs 3.8% p < 0.01) [25].
The risk of SCD is not similar for every patient. Rassi et al. [26] developed and validated a 
risk score for predicting death in 424 patients followed for a mean of 7.9 years. They identi‐
fied six independent prognostic factors: New York Heart Association (NYHA) class III or IV 
(5 points), cardiomegaly on chest radiography (5 points), segmental or global wall motion 
abnormality on echocardiogram (3 points), non‐sustained VT on Holter monitoring (3 points), 
low QRS voltage (2 points) and male sex (2 points). This score classifies in three groups of risk 
for 10 years mortality: low risk (0–6 points, 10%), intermediate risk (7–11 points, 44%) and 
high risk (12–20 points, 84%). In this study the rate of SCD was 2.4% for a year. Although the 
score risk was development for total mortality, all of the variables were also strong predictors 
for SCD, except low QRS voltage.
Other risk factors include syncope, spontaneous sustained VT, abnormalities on the 12‐lead 
electrocardiogram or echocardiogram, or sustained TV induced by programmed ventricu‐
lar stimulation (PVS). In 28 chagasic patients with sustained TV over a mean follow‐up of 
3816 months, deaths occurred in 13 patients (46.4%) and resulted from SCD in seven subjects 
[27]. Interestingly, in this study the prognosis was similar with non‐sustained VT. The pres‐
ence on echocardiogram of left ventricular dilatation and left apical ventricular aneurysm 
was associated with SCD [15]. In the same way, the presence of Q waves, frequent premature 
ventricular contractions, left anterior fascicular block (LAFB), or QT interval dispersion has 
been established predictors of SCD [28]. In 78 patients with CD and non‐sustained VT, PVS 
was carried out and sustained monomorphic VT was induced in 25 patients (32%) and VF in 
four (5.1%). Induction of sustained ventricular arrhythmias was the independent and main 
variable that predicted cardiac death (OR 2.17 CI 95% 1.23–3.83) [29].
In summary CD is associated with SCD, most commonly through VF, often preceded by sus‐
tained VT. There is a higher risk group that may be established by clinical criteria and invasive 
or noninvasive procedures (Table 1).
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3. ICD in Chagas disease
3.1. Secondary prevention of SCD
The use of ICD has become a main therapeutic strategy for prevention of sudden death.
A meta‐analysis of AVID (Antiarrhythmics versus implantable defibrillators), CIDS 
(Canadian Implantable Defibrillator Study) and CASH (Cardiac Arrest Study Hamburg) 
that evaluated utility of ICD in secondary prevention of SCD demonstrated that ICD ther‐
apy was associated with 50% (p = 0.0001) reduction in arrhythmic mortality and a 28% (p = 
0.006) reduction in total mortality [30]. Today, ICD is considered class I A recommendation 
in patients recovered of SCD [31]. However, in these studies there is no information about 
chagasic patients.
In a study of secondary prevention, 65 chagasic patients were compared with 70 non‐cha‐
gasic patients and were followed for the median time of 266 days. Appropriate ICD therapy 
occurred in 32 (49.2%) chagasic patients and in 19 (27.1%) of the control group (p = 0.005). 
There was a statistically significant difference in event‐free survival in the Chagas group. 
Finally, CD doubles the risk of the patient to have appropriate therapy (HR = 2.2) and appro‐
priate therapy or death (HR 2.2). The annual mortality rate was 17% [32].
Some authors have proposed the use of amiodarone alone for secondary prevention in chagasic 
patients. The limited evidence available does not favor this hypothesis. A study compared 
the outcomes of Chagas’ heart disease patients with life‐threatening ventricular arrhythmias, 
who were treated with ICD with a historical group treated with amiodarone alone. The ICD 
• Syncope
• NYHA class III–IV
• Male sex
• Spontaneous sustained VT
• Q wave
• Left anterior fascicular block
• QT interval dispersion
• Non‐sustained VT
• Frequent premature ventricular contractions
• Cardiomegaly on chest radiography
• Left ventricular dilatation
• Left apical ventricular aneurysm
• Segmental motion abnormality
• Sustained VT induced with PVS
NYHA, New York Heart Association; VT, ventricular tachycardia; PVS, programmed ventricular stimulation.
Table 1. Risk factors associated with sudden cardiac death in chagasic patients.
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group (76 patients) had higher use of beta‐blocker (p < 0.0001). Amiodarone was also used in 
90% of the ICD group. Therapy with ICD plus amiodarone produced 72% reduced risk of 
all‐cause mortality (p = 0.007) and a 95% reduced risk of sudden death (p = 0.007) compared 
with  amiodarone‐only therapy. The follow‐up was 36 ± 16 months for the ICD group and 
35 ± 17 months for the control group. There are ten deaths (4.7% per year) in the ICD group 
and nine deaths (11% per year) in the control group [33].
Several studies have evaluated over a long‐term follow‐up period the efficacy of ICD. A study 
included 116 consecutive patients with CD and an ICD implanted for secondary preven‐
tion. The average follow‐up was 45 months. In this survey 58 (50%) patients had appropriate 
shocks. A total of 31 patients died (7.1% annual mortality rate) [34]. Another study assessed 
a cohort with 65 patients (51 in secondary prevention) with median follow‐up of 40 ± 26.8 
months. Among the patients 23 (36.5%) had appropriate shocks. A total of 13 (20%) patients 
died (6.1% of annual mortality rate) and there was no sudden death [35]. A survey with 90 
patients with ICD for secondary prevention found, with median follow‐up of 756 ± 581 days, 
31 (34%) deaths (16.4% of annual mortality rate) [36]. Maybe the largest study in secondary 
prevention with chagasic patients evaluated 148 subjects with mean follow‐up was 12 ± 7 
months. During the follow‐up 15 patients died (10.2%) [37].
Patients with chronic CD with life‐threatening ventricular arrhythmias have an annual mor‐
tality rate between 8.6% and 11% when they are treated with amiodarone [33, 38]. However, 
survival probability at 3 years of follow‐up is 30% in patients with no treatment and 20% 
treated with quinidine or procainamide [39].
No randomized clinical trial has assessed the effect of ICD therapy on outcome of Chagas’ 
disease patients with malignant ventricular arrhythmias thus far. However, with available 
information it is obvious that patients without treatment (mortality 70% at 3 years) or with 
class IA antiarrhythmic (mortality 80% at 3 years, possibly due to antiarrhythmics) have high 
mortality [39] and need other options. Amiodarone has been used for a long term in these 
patients, with an annual mortality rate between 8.6 and 11% [33, 38].
ICD is associated with an annual mortality rate between 6.1 and 17% [32–37]. Thus, the 
impact of ICD implantation on all‐cause mortality has shown inhomogeneous results, pos‐
sibly related to differences among populations and treatments in the studies. The only study 
that compared ICD plus amiodarone against amiodarone alone demonstrated reduction of 
the risk of all‐cause mortality and sudden death. Patients with left ventricular ejection fraction 
(LVEF) < 40% derived more survival benefit [33].
Although some authors have suggested the need of a randomized clinical trial to demonstrate 
the usefulness of ICD in this population [40], most groups working with chagasic patients are 
extrapolating the secondary prevention ICD indications proposed by international guidelines 
[31] as reflected by the I Latin American guidelines for the diagnosis and treatment of Chagas 
heart disease [41].
On the other hand, these patients have differences with other patients with non‐Chagas car‐
diomyopathy. In the meta‐analysis of the ICD secondary prevention trials, the authors found 
that the mean LVEF was 34 ± 15% [30]. Conversely, the mean LVEF among the studies with 
chagasic patients is higher (37–47%); it is suggesting that CD is more arrhythmogenic heart 
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disease or less dependent of the ventricular damage [32–37]. Moreover, a substantial number 
of the included patients had no left ventricular dysfunction.
Another difference between chagasic or non‐chagasic patients with ICD for secondary pre‐
vention is the age at the time of implantation. In the meta‐analysis was 63 ± 11 years, while in 
chagasic patients was lower (54–59 years) [32–37].
There are differences with life‐threatening ventricular arrhythmias; Chagas’ disease patients 
tend to experience more shocks. In a study during the first 6 months of follow‐up, 17 of the 
20 (85%) chagasic patients received at least one appropriate therapy. In the control group 
(ischemic patients), 18 of the 35 (51%) received one ICD shock (RR 1.6; p < 0.02) [42]. In other 
studies, the frequency of appropriate shock was 36–64% in the follow‐up for 1–2 years [32–37].
Otherwise, several groups have shown predictors of all‐cause mortality in patients with 
Chagas heart disease receiving ICD. The most common predictors of mortality were NYHA 
class III (HR 3.09 95% CI 1.37‐6.98, p = 0.0064), LVEF (HR 0.97 95% CI 0.94‐0.99, p = 0.04) and 
low cumulative right ventricular pacing < 40% (HR 0.23 95% CI 0.11‐0.49, p = 0.0001) [34].
In another study the only predictor was the number of shocks; probability of survival for 
patients receiving more than four shocks by day 30 post‐implant was 75% at 30 days and 19% 
at 60 days, whereas probability of survival for patients receiving up to four shocks by day 30 
were 97% at 30 days, 96% at 120 days, 94% at 270 days and 89% at at 360 days of follow‐up 
(p = 0.00005). Mean life expectancy was 2.1 months (95% CI 0.79–3.4) in patients receiving 
more than four shocks by day 30 and 46.5 months in patients receiving up to four shocks by 
day 30 (p = 0.0005) [36]. Pereira et al. found predictors of poor prognosis: a LVEF < 30% and 
low education [35] and another group showed that patients older than 65 years of age and 
LVEF < 30% were independent predictors of all‐cause 1 year mortality [37]. It is important 
to note that in the studies of secondary prevention, the medical treatment was incomplete 
for the use of beta‐blocker, angiotensin‐converting enzyme inhibitors (ACEI)/Angiotensin II 
receptor blockers (ARB) or spironolactone.
Although several authors have suggested that amiodarone is the initial management in cha‐
gasic patients with VT without hemodynamic instability and ICD in other patients [43], most 
Secondary prevention of SCD
• ICD therapy + amiodarone (class I)
Primary prevention of SCD
• ICD therapy in chagasic patients with LVEF < 40% (class I)
Treatment of CHF
• CRT in patients with LVEF < 35% + OMT + LBBB + NYHA class II–IV (class I)
• CRT in patients with LVEF < 35% + OMT + RBBB + NYHA class III–IV (class II B)
SCD, sudden cardiac death; ICD, implantable cardioverter defibrillator; LVEF, left ventricular ejection fraction; OMT, optimal 
medical treatment; LBBB, left bundle branch block; NYHA, New York Heart Association; RBBB, right bundle branch block.
Table 2. Indications of ICD and CRT in chagasic patients.
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groups recommend ICD therapy as an initial approach possibly associated with the use of 
amiodarone (Table 2) [31].
3.2. Primary prevention of SCD
If the evidence, in the management of patients with life‐threatening ventricular arrhyth‐
mias, is not of great quality, the information is even poor in primary prevention of SCD. As 
expected, no randomized controlled study has been carried out.
In the only study available, Cardinalli‐Neto et al. included 32 patients with a LVEF < 35%, 
receiving standard therapy for chronic systolic heart failure and to have a reasonable expec‐
tation of 1‐year survival after device implantation; all patients were on NYHA class II and 
none had syncope. Nineteen (59%) patients had a positive serology for CD. Notably, 87% of 
patients were on beta‐blocker and 100% were on ACEI/ARB.
Sustained VT was detected in four (21%) patients with Chagas heart disease and in two (15%) 
patients with non‐Chagas (p = NS). VF was observed in four (21%) patients with Chagas car‐
diomyopathy and in two (15%) with non‐Chagas patients (p = NS). Median time to first event 
was 78 (34–151) days in Chagas and 173 (71–593) days in non‐Chagas patients (p = 0.005). 
Median follow‐up was 292 (78–845) days in Chagas and 654 (159–987) days in non‐Chagas 
(p = 0.005) here was no difference in mortality) [44].
Non‐sustained VT is an independent predictor of all‐cause mortality and SCD in patients 
with Chagas cardiomyopathy with LVEF from 30 to 50% [45]. In these patients the prognosis 
role of PVS has been studied. In 78 chagasic patients with mean LVEF 48% and non‐sustained 
VT, electrophysiologic testing was realized. In 25 (32%) out of 78 patients, sustained VT was 
induced. During a mean follow‐up of 56 ± 38 months, 22 (28%) patients died, SCD affecting 16 
(73%) of them. A significant association between inducible sustained VT and SCD was found 
(p < 0.05). All patients induced with sustained VT received amiodarone [29].
Actually, European guidelines recommend using ICD in chagasic patients with LVEF < 40% 
[31]. However, a significant number of SCD occur in patients with LVEF > 40% and in these 
subjects, there is no adequate way to establish their risk. PVS might be an option, but new and 
larger studies are necessary (Table 2).
4. Heart failure in Chagas disease
After the acute phase of the disease, most patients enter a clinically asymptomatic chronic 
phase without electrocardiographic or radiological abnormalities in the heart, which has been 
described as the indeterminate chronic form. Nevertheless, when these individuals are sub‐
jected to echocardiogram or radionuclide, ventriculography is common to find abnormalities; 
endomyocardial biopsy shows abnormalities in 60% of the cases [46]. Every year 2.5% would 
evolve into cardiac or digestive symptomatic forms [47]. CHF affects approximately 5% of a 
general unselected CD population and up to 76% of patients followed at outpatient services 
in tertiary referral centers [48].
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Chagasic cardiomyopathy is a chronic myocarditis that affects all chambers, the parasympa‐
thetic cardiac nerves and all levels of the system [49]. Four possible mechanisms have been 
suggested: cardiac parasympathetic neuronal depopulation, immune‐mediated myocardial 
injury, parasite persistence in cardiac tissue with secondary antigenic stimulation and coro‐
nary microvascular abnormalities [25, 49].
CD is the principal cause of CHF in areas where the disease is endemic [50]. Mortality is still 
high even in the current era of heart failure therapy (around 20% annual) [51]. When com‐
pared with other etiologies, outcome is poorer [52].
CD is associated with ventricular conduction delay. In a large population date base on pri‐
mary case patients, 7590 had CD. The electrocardiogram showed right bundle branch block 
(RBBB) in 22.7%, left anterior hemiblock (LAHB) in 22.5%, RBBB + LAH in 13,74% and left 
bundle branch block (LBBB) in 3.07% of patients [53]. In chagasic patients an increase in QRS 
duration correlated with a decrease in LVEF and increase in left ventricular diastolic diameter 
[54]. On echocardiographic evaluation, the presence of apical or inferobasal aneurysms in the 
left ventricle is common (Figures 1 and 2).
The beneficial effects on survival and morbidities of drugs observed in non‐Chagas disease 
heart failure are extrapolated to Chagas’ disease patients. Medical treatment of CD heart 
failure is not supported by strong evidence. Small studies have shown that neurohormonal 
inhibition can improve both symptoms and left ventricular function. However, a systematic 
review of Cochrane found very low‐quality evidence for the effects of carvedilol compared 
with placebo for treating heart failure in people with CD [55]. On the other hand, chagasic 
Figure 1. Echocardiogram with apical aneurysm in the left ventricle in a patient with Chagas cardiomyopathy.
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patients frequently have lower blood pressure and a higher incidence of bradyarrhythmias 
and may not tolerate target doses of angiotensin‐converting enzyme inhibitors (ACEI) and 
beta‐blockers.
In conclusion CHF secondary to CD has higher mortality and problems with the neurohor‐
monal blockade, related to difficulty in reaching optimum doses of beta‐blockers and ACEI.
5. Cardiac resynchronization therapy
Cardiac resynchronization therapy (CRT) is an established therapeutic modality for patients 
with non‐Chagas heart disease with LVEF < 35%, in appropriate medical management and 
LBBB with a QRS 150 mseg (class I). In patients with non‐LBBB pattern, the recommendation 
is class II [56].
Evidence of the usefulness of CRT in CD is scarce. Araujo et al. analyzed 72 chagasic patients 
in NYHA class III or IV, who underwent CRT. The average clinical follow‐up was 46.6 month 
(4–79). At the end of the evaluation, 87.4% of patients were in NYHA class I or II and they 
had increase of the LVEF. There was an overall mortality of 34.7% of the patients underwent 
implantation of the electrode of the left ventricle through a left anterior mini‐thoracotomy. 
All patients were on beta‐blocker therapy and 70% on ACEI. Mean QRS duration was 148.1 
17 mseg, 47% was with LBBB, 15% on permanent right ventricular paging and mean LVEF 
was 27.3 ± 7.7% [57].
Figure 2. Real‐time image integration of the left ventricle with computed tomography and electroanatomical map with 
EnSite NavX. Image of the left ventricle with apical and inferobasal aneurysm.
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In another study 30 chagasic patients in NYHA class III or IV undergone to right ventricu‐
lar bifocal pacing. No change in the LVEF after 6 months of follow‐up. However, a marked 
increase in arrhythmic episodes was observed.. The mortality rate was 43% in the first year 
of follow‐up.
In a small study, 29 patients (52% chagasic) with conventional pacemakers implanted in the 
right ventricular apical area, in NYHA class III/IV refractory to drug therapy and LVEF < 35%, 
underwent CRT. During the follow‐up of 22.7 ± 13 months, 86.2% of the patients benefited 
from CRT. However, there was no differential analysis of the chagasic patients [58].
There is low frequency of complete LBBB (16%) in chagasic patients with CHF. The most 
frequently found intraventricular conduction dysfunction is RBBB alone or with LAFB [51]. 
Nowadays, there is controversial evidence to support the use of CRT in patients without 
LBBB. Recently, a small study with 78 patients with RBBB showed that single‐site pacing of 
the right ventricular septum near the proximal right bundle resulted in a marked decrease in 
QRS duration and often normalized the ECG [59], so that there may be new alternatives of 
stimulation in this patient group.
In conclusion the evidence of CRT in CHF of chagasic etiology is poor; however, in patients 
with LBBB, LVEF < 35% with adequate medical therapy CRT is indicated. In patients with 
RBBB, CRT is probably unhelpful. If RBBB is attached to LAFB, some authors consider useful 
biventricular pacing, but studies proving this theory are necessary.
6. Other treatments
Heart transplantation is an option in patients with refractory CHF. There are many concerns 
with regard to the usefulness in chagasic patients because of T. cruzi infection reactivation, 
the adequate immunossuppresive protocol and long‐term results. A systematic review found 
that survival probability at 1 month, 1 year, 4 years and 10 years of follow‐up was 83, 71, 57 
and 46%, respectively. Such an outcome was better than that seen in non‐Chagas patients [60]. 
Later, a study with 107 chagasic patients with follow‐up between 30 and 168 months found 
the highest mortality (42.9%) [61]. Transplantation in Chagas’ disease has several problems 
that differ from other etiologies due to the possibility of disease reactivation and the increased 
possibility of emergence of cancers. However, transplantation is the only treatment able to 
modify the natural progression of the disease in its terminal phase.
The utility of the left ventricular circulatory support as bridge to heart transplantation has 
been little studied. A study with 6 patients with chagasic cardiomyopathy, the mean time of 
circulatory support was 27 days, authors found that 2 patients were bridged to heart trans‐
plantation successfully and other four patients died.
Sustained VT is common in chagasic patients. The most frequent mechanism is scar‐related 
reentry; the circuit may be subepicardial, intramyocardial, or subendocardial (Figure 3). 
Reports have described a higher prevalence of epicardial VT (37%). The electrophysiologi‐
cal signs show delayed potentials predominantly in the target area during mapping in sinus 
The Role of the Clinical Cardiac Electrophysiologist in the Management of Congestive Heart Failure94
rhythm and presystolic activity. Meso‐diastolic and continuous activities are also frequent 
in the original place of VT. The critical isthmus of the reentrant circuit may be confirmed by 
entrainment maneuvers or interruption of VT during the application of RF in these places. In 
general, the site of origin of well‐tolerated recurring VT can be identified and the VT inter‐
rupted in 60–80% of the patients, but rapid and poorly tolerated SVT is frequently induced in 
the final assessment of the procedure. During long‐term follow‐up, at least 50% of the patients 
have clinical relapse [41]. The main indication for catheter ablation is ICD shocks despite 
antiarrhythmic therapy.
Figure 3. Image of Figure 2 with voltage sinus rhythm map showing extensive scar inferobasal.
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7. Conclusions
CD is an important cause of CHF in Latin America; migration has become this disease in a 
probable cause of CHF in other countries of the world. CD is associated with high prevalence 
of SCD; ICD is indicated as therapy class I in secondary prevention of SCD. ICD is also indi‐
cated as therapy class I in primary prevention of SCD in chagasic patients with LVEF < 40% 
with optimal medical treatment (OMT). The utility of PVS should be investigated in patients 
with non‐sustained VT and LVEF > 40%.
CHF is very common in patients with CD. CRT is indicated as therapy class I in patients with 
LBBB + LVEF < 35% + OMT. Indication in patients with non‐LBBB is controversial and new 
and large studies are necessary.
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